C Hulin
Overview
Explore the profile of C Hulin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chalopin T, Macro M, Decaux O, Royer B, Gounot R, Bobin A, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Oct;
25(2):e103-e109.e1.
PMID: 39462749
Introduction: Multiple myeloma patients aged 80 years and older are a population more prone to comorbidities and frailty. We aim to describe the real-life management and outcomes of this population....
2.
Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, et al.
Ann Hematol
. 2023 Jun;
102(8):2137-2151.
PMID: 37301786
Ixazomib (IXA) is an oral proteasome inhibitor (PI) used in combination with lenalidomide and dexamethasone (IXA-Rd) for patients with relapsed and/or refractory multiple myeloma (RRMM). The REMIX study is one...
3.
Fouquet G, Pegourie B, Macro M, Petillon M, Karlin L, Caillot D, et al.
Ann Oncol
. 2016 Jan;
27(5):902-7.
PMID: 26787238
Background: The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had...
4.
Usmani S, Cavenagh J, Belch A, Hulin C, Basu S, White D, et al.
J Med Econ
. 2015 Oct;
19(3):243-58.
PMID: 26517601
Objective: To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from...
5.
Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, et al.
Rev Med Interne
. 2015 Aug;
36(9):613-8.
PMID: 26257103
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib)...
6.
Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, et al.
Leukemia
. 2013 Jul;
28(3):675-9.
PMID: 23892719
Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real...
7.
Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, Godmer P, et al.
Leukemia
. 2012 Aug;
27(2):473-81.
PMID: 22874878
Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent relapse in...
8.
Damaj G, Malard F, Hulin C, Caillot D, Garidi R, Royer B, et al.
Leuk Lymphoma
. 2011 Sep;
53(4):632-4.
PMID: 21916831
One hundred and ten patients with multiple myeloma were treated with bendamustine as part of a French compassionate use program. To receive bendamustine, patients had to present with relapsed or...
9.
Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H, et al.
Leukemia
. 2011 Jul;
26(1):158-9.
PMID: 21799511
No abstract available.
10.
Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J, et al.
Leukemia
. 2011 Jul;
26(1):149-57.
PMID: 21799510
Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural...